Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jagsonpal Pharmaceuticals Ltd

₹ 640 8.21%
22 Nov 4:00 p.m.
jagsonpal.com BSE: 507789 NSE: JAGSNPHARM
About

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]

Key Points

Business Overview:[1][2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands

Website BSE NSE
  • Market Cap ₹ 1,697 Cr.
  • Current Price ₹ 640
  • High / Low ₹ 653 / 270
  • Stock P/E 63.4
  • Book Value ₹ 74.4
  • Dividend Yield 0.77 %
  • ROCE 17.0 %
  • ROE 13.0 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 54.5%
  • Debtor days have improved from 25.8 to 19.2 days.

Cons

  • Stock is trading at 8.65 times its book value
  • The company has delivered a poor sales growth of 4.58% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
59 54 51 61 61 60 55 60 58 47 43 61 75
50 49 50 53 48 52 50 52 49 44 41 51 58
Operating Profit 9 6 1 7 13 9 5 9 8 3 3 10 16
OPM % 16% 10% 2% 12% 21% 14% 10% 14% 14% 7% 6% 17% 22%
0 2 0 -3 1 2 3 2 2 3 2 -2 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 1 0 0 0 0 0 0 0 0 1 2
Profit before tax 9 7 0 4 14 10 7 10 10 5 5 7 15
Tax % 30% 24% 32% 24% 24% 21% 24% 26% 25% 25% 22% 25% 25%
7 5 0 3 10 8 6 7 7 4 4 5 11
EPS in Rs 2.50 2.07 0.12 1.11 3.97 2.97 2.14 2.86 2.85 1.51 1.34 2.01 4.33
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
166 144 138 143 144 127 167 159 188 218 237 209 227
156 133 129 132 138 138 157 150 169 192 203 186 194
Operating Profit 10 11 9 12 6 -11 9 9 19 26 34 23 33
OPM % 6% 7% 6% 8% 4% -9% 6% 5% 10% 12% 14% 11% 14%
0 0 0 1 13 0 1 3 4 3 2 9 5
Interest 5 5 4 5 3 1 1 1 1 0 0 1 1
Depreciation 3 3 3 3 2 0 1 1 1 2 1 2 4
Profit before tax 3 3 2 4 14 -12 9 9 22 27 35 30 32
Tax % 28% 16% 30% 20% 18% -1% 20% 16% 22% 29% 23% 25%
2 2 1 3 12 -12 7 8 17 19 27 22 24
EPS in Rs 0.70 0.81 0.45 1.24 4.53 -4.41 2.76 3.00 6.51 7.20 10.20 8.50 9.19
Dividend Payout % 72% 62% 22% 8% 2% -2% 9% 17% 15% 56% 49% 59%
Compounded Sales Growth
10 Years: 4%
5 Years: 5%
3 Years: 4%
TTM: -3%
Compounded Profit Growth
10 Years: 27%
5 Years: 25%
3 Years: 10%
TTM: -6%
Stock Price CAGR
10 Years: 34%
5 Years: 87%
3 Years: 58%
1 Year: 53%
Return on Equity
10 Years: 8%
5 Years: 14%
3 Years: 16%
Last Year: 13%

Balance Sheet

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 13 13 13 13 13 13 13 13 13 13 13 13 13
Reserves 85 85 82 85 97 85 91 98 109 120 146 174 184
33 36 39 38 8 8 4 5 7 0 6 9 10
21 22 19 22 25 23 28 31 35 31 30 21 51
Total Liabilities 153 156 154 159 143 130 136 147 164 164 195 217 258
58 56 52 52 22 21 22 22 26 23 24 9 99
CWIP 2 2 0 0 0 3 4 4 0 0 0 0 0
Investments 0 0 0 0 0 0 0 11 15 51 1 0 0
92 98 102 108 121 105 110 109 123 91 170 208 159
Total Assets 153 156 154 159 143 130 136 147 164 164 195 217 258

Cash Flows

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
12 8 4 9 -3 -2 31 11 28 7 47 35
-3 -1 -0 -2 41 -3 -1 -11 -2 -26 -58 -25
-8 -4 -1 -6 -34 -1 -6 -1 -7 -18 -0 -9
Net Cash Flow 0 2 2 1 5 -6 24 -0 19 -36 -11 2

Ratios

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 93 115 119 106 100 73 45 49 25 26 32 19
Inventory Days 127 173 176 246 295 307 164 191 134 122 82 68
Days Payable 28 29 42 60 56 54 59 76 82 76 66 35
Cash Conversion Cycle 192 259 252 292 339 325 150 164 77 72 48 53
Working Capital Days 130 155 171 169 174 173 76 66 45 59 36 59
ROCE % 6% 6% 5% 7% 3% -10% 9% 9% 18% 20% 25% 17%

Shareholding Pattern

Numbers in percentages

6 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
70.34% 68.71% 68.71% 68.72% 68.72% 68.72% 68.72% 68.72% 68.48% 68.09% 68.04% 67.98%
0.20% 0.00% 0.00% 0.13% 0.11% 0.10% 0.37% 0.38% 0.53% 0.73% 1.10% 2.30%
0.00% 0.67% 0.68% 0.28% 0.77% 0.82% 0.82% 0.82% 0.82% 0.84% 0.84% 0.11%
29.46% 30.61% 30.61% 30.85% 30.40% 30.34% 30.07% 30.07% 30.16% 30.33% 30.01% 29.63%
No. of Shareholders 20,03117,10016,19414,95214,53514,08413,78216,04115,78516,28215,74815,633

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls